From famine to feast: Developing early-phase combination immunotherapy trials wisely

Daphne Day, Arta M. Monjazeb, Elad Sharon, S. Percy Ivy, Eric H. Rubin, Gary L. Rosner, Marcus O. Butler

Research output: Contribution to journalArticleResearchpeer-review

14 Citations (Scopus)


Not until the turn of this century has immunotherapy become a fundamental component of cancer treatment. While monotherapy with immune modulators, such as immune checkpoint inhibitors, provides a subset of patients with durable clinical benefit and possible cure, combination therapy offers the potential for antitumor activity in a greater number of patients. The field of immunology has provided us with a plethora of potential molecules and pathways to target. This abundance makes it impractical to empirically test all possible combinations efficiently. We recommend that potential immunotherapy combinations be chosen based on sound rationale and available data to address the mechanisms of primary and acquired immune resistance. Novel trial designs may increase the proportion of patients receiving potentially efficacious treatments and, at the same time, better define the balance of clinical activity and safety. We believe that implementing a strategic approach in the early development of immunotherapy combinations will expedite the delivery of more effective therapies with improved safety and durable outcomes.

Original languageEnglish
Pages (from-to)4980-4991
Number of pages12
JournalClinical Cancer Research
Issue number17
Publication statusPublished - 1 Sep 2017
Externally publishedYes

Cite this